Table of Contents
- 1.1. The Immune System
- 1.2. Scope of the Report
Chapter 2 ALZHEIMER' S DISEASE
- 2.1. Alzheimer' s Disease Pathophysiology, Epidemiology, and Current
Treatments
- 2.2. Why Immunotherapies or Vaccines for Treatment of Alzheimer' s Disease?
- 2.3. Companies Developing Immunotherapies or Vaccines for Alzheimer' s
Disease
- AFFiRiS
- Baxter
- Novartis and Cytos Biotechnology
- Eli Lilly
- Genentech and AC Immune
- GlaxoSmithKline
- Merck & Co.
- Octapharma
- Pfizer
- Roche and MorphoSys
- Wyeth and Elan
- 2.4. Business Considerations: Immunotherapies for Alzheimer' s Disease
Chapter 3 ADDICTION
- 3.1. Pathophysiology, Epidemiology, and Current Treatments
- Cocaine Addiction
- Nicotine Addiction (Smoking Cessation)
- 3.2. Why Immunotherapies for Addiction?
- 3.3. Companies Developing Immunotherapies for Cocaine Addiction or Smoking
Cessation
- Cocaine Addiction
- Celtic Pharma
- Nicotine Addiction (Smoking Cessation)
- Celtic Pharma
- Nabi Biopharmaceuticals
- Novartis and Cytos Biotechnology
- 3.4. Business Considerations: Immunotherapies for Cocaine Addiction or
Smoking Cessation
Chapter 4 OTHER NEUROLOGY INDICATIONS FOR MONOCLONAL ANTIBODIES AND IMMUNOTHERAPIES
- 4.1. Pathophysiology, Epidemiology, and Current Treatments
- Multifocal Motor Neuropathy
- Pain
- Post-Polio Syndrome
- Other Potential Neurology Indications
- 4.2. Why Immunotherapies for Treatment of Pain?
- 4.3. Companies Developing or Marketing Immunotherapies for Other
Neurological Indications
- Alexion Pharmaceuticals' Soliris (eculizumab)
- Array BioPharma' s ARRY-797
- Baxter' s Immune Globulin
- CSL Behring' s Immune Globulin
- GlaxoSmithKline' s 249320 (GSK249320)
- Pfizer' s Tanezumab
- Pharmalink' s Xepol (XP-28)
- Talecris Biotherapeutics' Gamunex
- 4.4. Business Considerations: Immunotherapies for Other Neurological
Indications
Chapter 5 CARDIOVASCULAR DISEASES INCLUDING THROMBOSIS
- 5.1. Pathophysiology, Epidemiology, and Current Treatments
- Angina
- Atherosclerosis
- Dyslipidemia (Elevated Cholesterol and Other Lipids)
- Hypertension
- Venous Thromboembolism
- Digoxin Toxicity
- 5.2. Why Immunotherapies for Selected Cardiovascular Diseases?
- 5.3. Companies Developing Immunotherapies for Cardiovascular Diseases
- Ablynx' ALX-0081 and ALX-0681
- BTG' s DigiFab
- BTG' s Angiotensin Therapeutic Vaccine
- Centocor Ortho Biotech' s and Eli Lilly' s ReoPro (abciximab)
- Cytos Biotechnology' s CYT006-AngQb
- Genentech' s and BioInvent International' s BI-204 (anti-oxLDL)
- GlaxoSmithKline' s Digibind
- Roche' s and Genmab' s R1512
- ThromboGenics' and BioInvent International' s TB-402
- 5.4. Business Considerations: Immunotherapies for Cardiovascular Diseases
Chapter 6 HEMATOLOGY/BLOOD DISORDERS
- 6.1. Pathophysiology, Epidemiology, and Current Treatments
- Idiopathic (Immune) Thrombocytopenic Purpura (ITP)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Rh Incompatibility and Hemolytic Disease of the Newborn (HDN)
- 6.2. Why Immunotherapies for Selected Hematology/Blood Disorders?
- 6.3. Companies Developing or Marketing Immunotherapies for
Hematology/Blood Disorders
- Alexion Pharmaceuticals' Soliris (eculizumab)
- Amgen' s Nplate (romiplostim)
- Immune Globulin Preparations for Idiopathic (Immune) Thrombocytopenic
Purpura (ITP)
- Rho(D) Immune Globulin Preparations and LFB' s Anti-Rhesus D Monoclonal
Antibody
- 6.4. Business Considerations: Immunotherapies for Hematology/Blood
Disorders
Chapter 7 OPHTHALMOLOGY
- 7.1. Pathophysiology, Epidemiology, and Current Treatments
- Age-Related Macular Degeneration (AMD)
- Diabetic Retinopathy and Diabetic Macular Edema
- Retinal Vein Occlusion
- Uveitis
- 7.2. Why Antibody-Based Therapies for Selected Ophthalmic Diseases?
- 7.3. Companies Developing Antibody-Based Therapies for Ophthalmic Diseases
- ESBATech' s ESBA105
- Genentech' s and Novartis' Lucentis (ranibizumab)
- Lpath' s iSONEP (sonepcizumab)
- 7.4. Business Considerations: Antibody-Based Therapies for Ophthalmic
Diseases
Chapter 8 OSTEOPOROSIS AND OTHER BONE METABOLISM DISORDERS
- 8.1. Pathophysiology, Epidemiology, and Current Treatments
- 8.2. Why Antibodies for Selected Bone Metabolism Disorders?
- 8.3. Companies Developing Antibodies for Osteoporosis and Other Bone
Metabolism Disorders
- Ablynx' ALX-0141
- Amgen' s Denosumab
- Amgen' s and UCB Pharma' s Sclerostin Ab
- 8.4. Business Considerations: Antibodies for Osteoporosis and Other Bone
Metabolism Disorders
Chapter 9 TYPE 2 DIABETES
- 9.1. Pathophysiology, Epidemiology, and Current Treatments
- 9.2. Why Monoclonal Antibodies for Type 2 Diabetes?
- 9.3. Companies Developing Monoclonal Antibodies for Type 2 Diabetes
- Amgen' s AMG 477
- Cytos Biotechnology' s CYT013-IL1bQb
- Novartis' Ilaris (canakinumab)
- Xoma' s XOMA 052
- 9.4. Business Considerations: Monoclonal Antibodies for Type 2 Diabetes
Chapter 10 OTHER APPLICATIONS OF ANTIBODIES AND IMMUNOTHERAPIES
- 10.1. Companies Developing Antibodies, Antibody-Based Drugs, and
Anti-inflammatory Drugs for Other Indications
- Amgen' s AMG 745
- AstraZeneca' s and BTG' s CytoFab
- BTG' s CroFab and ViperaTAb
- ESBATech' s ESBA105
- FibroGen' s FG-3019
- Genzyme' s GC1008
- GlaxoSmithKline' s 656933 (Sb656933)
- Novartis' Ilaris (canakinumab)
- Immune Globulin Preparations for Other Indications
- 10.2. Business Considerations: Antibodies and Immunotherapies for Other
Indications
Chapter 11 EXPERT INTERVIEWS
- 11.1. Steven Glazer, MD; Senior Vice President, Development; BioInvent
International
- 11.2. Josefin-Beate (Josi) Holz, MD, Chief Medical Officer & Eva-Lotta
Allan, Chief Business Officer; Ablynx
- 11.3. David Y. Liu, PhD, Vice President, Research & William Hodder, Vice
President, Business Development; FibroGen
- 11.4. Steve Pakola, MD; Chief Medical Officer; ThromboGenics
- 11.5. Andrea Pfeifer, PhD; Chief Executive Officer; AC Immune
- 11.6. Roger Sabbadini, PhD; Founder, Vice President, Chief Scientific
Officer; Lpath
- 11.7. Walter Schmidt, PhD; Chief Executive Officer; AFFiRiS
References
Company Index with Web Addresses
|
Related Report
|
View Cart
